A Case Report of Al-Amyloidosis with «Hepatic Disguise» of Nephrotic Syndrome

   Amyloidosis is characterized by damage to several organ systems, which leads to diagnostic delays and progression of the pathological process. The described clinical case demonstrates a long diagnostic search in a patient with AL-amyloidosis. According to the literature, the most often described manifestation of the disease is kidney damage that manifests as nephrotic syndrome. This case is interesting because the reason for hospitalization was liver damage. Laboratory tests revealed cholestatic and cytolytic syndromes and dyslipidemia. Differential diagnostic included diseases with liver damage. In the hospital nephrotic syndrome was identifi ed, renal biopsy was performed that proved the diagnosis of AL-amyloidosis with combined damage to the gastrointestinal tract, liver and kidneys.

1. Lysenko (Kozlovskaya) L.V., Rameev V. V., Moiseev S., et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin. Pharmacol. Therapy. 2020; 29(1):13-24 [In Russian]. DOI: 10.32756/0869-5490-2020-1-13-24.

2. Desport E., Bridoux F., Sirac C., et al. Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales. Al amyloidosis. Orphanet J Rare Dis. 2012 Aug 21; 7: 54. DOI: 10.1186/1750-1172-7-54.

3. Manwani R., Cohen O., Sharpley F., et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019; 134(25): 2271-2280. DOI: 10.1182/blood.2019000834.

4. Pinney J. H., Smith C. J., Taube J. B., et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013 May; 161(4): 525-32. DOI: 10.1111/bjh.12286.

5. Kyle R. A., Larson D. R., Kurtin P. J., et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019 Mar; 94(3): 465-471. DOI: 10.1016/j.mayocp.2018.08.041.

6. Falk R. H., Comenzo R. L., Skinner M. The systemic amyloidoses. N Engl J Med. 1997; 337(13): 898-909. DOI: 10.1056/NEJM199709253371306.

7. Vaxman I., Gertz M. When to Suspect a Diagnosis of Amyloidosis. Acta Haematol. 2020; 143(4): 304-311. DOI: 10.1159/000506617.

8. Gertz M. A., Comenzo R., Falk R. H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10^th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4): 319-28. DOI: 10.1002/ajh.20381.

9. Loustaud-Ratti V. R., Cypierre A., Rousseau A., et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011; 18(1): 19-24. DOI: 10.3109/13506129.2010.543443.

10. Mikhaleva L. M., Gioeva Z. V., Rёken K. Histological and immunohistochemical examinations in the diagnosis of hepatic amyloidosis. Russian Journal of Archive of Patology. 2015; 77(4): 11-16. (In Russ.)]. DOI: 10.17116/patol201577411-16.

11. Picken M. M. New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens. 2007; 16(3): 196-203. DOI: 10.1097/MNH.0b013e3280bdc0db.

12. Zhang X., Tang F., Gao Y. Y., et al. Hepatomegaly and jaundice as the presenting symptoms of systemic light-chain amyloidosis: A case report. World J Gastrointest Oncol. 2024 Feb 15; 16(2): 550-556. DOI: 10.4251/wjgo.v16.i2.550.

13. Kottavadakkeel N., Rajaram A. Hepatic Involvement as the Sole Presentation of Systemic Amyloid Light Chain (AL) Amyloidosis: A Diagnostic Challenge. Cureus. 2023 Oct 19; 15(10): e47310. DOI: 10.7759/cureus.47310.